A novel copper-catalyzed method for producing morphinan derivatives having diaryl ether skeleton
The use of a monovalent copper compound and zero-valent metallic copper catalyst system in the Ullmann reaction addresses reproducibility issues, enabling high-purity and efficient industrial production of morphinan derivatives with diaryl ether skeletons.
Patent Information
- Application Number
- JP2022545738
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-08-28
- Filing Date
- 2021-08-27
- Publication Date
- 2024-11-14
- Estimated Expiration
- 2041-08-27
AI Technical Summary
Existing methods for producing morphinan derivatives with a diaryl ether skeleton face challenges in reproducibility and unsuitability for industrial-scale production due to incomplete reactions and the need for additional copper powder during the Ullmann reaction.
A novel catalyst system using a monovalent copper compound, such as cuprous chloride or cuprous oxide, in combination with zero-valent metallic copper, facilitates the Ullmann coupling reaction to convert phenolic hydroxyl groups into phenol ether bonds, ensuring high conversion and purity.
This method enables the industrial production of morphinan derivatives with high conversion rates and purity, addressing the limitations of previous methods by providing a reliable and efficient synthesis process.
Smart Images

Figure 0007583820000001 
Figure 0007583820000002 
Figure 0007583820000003
Abstract
Description
[Technical field]
[0001] The present invention relates to a method for producing a morphinan derivative having a diaryl ether skeleton, in which a phenolic hydroxyl group of the morphinan derivative is converted into a phenol ether bond by Ullmann coupling using a novel copper catalyst. This application claims priority based on Japanese Patent Application No. 2020-145073, filed on August 28, 2020, the contents of which are incorporated herein by reference. [Background technology]
[0002] It is known that there are three subtypes of opioid receptors: μ, δ, and κ, and morphine, which has a strong affinity for μ receptors, has long been used as an analgesic. Morphine has a strong analgesic effect, but it is also known to cause adverse events such as dependence, respiratory depression, and constipation via the μ receptor. On the other hand, it is known that δ receptor-mediated analgesic effects are also observed, but δ receptor agonists are not involved in the adverse events observed with morphine. Therefore, it is believed that agonists selective for δ receptors may be better analgesics than morphine, and research into their creation is being actively conducted. However, there are no δ receptor agonists approved as therapeutic or preventive drugs yet.
[0003] Patent Documents 1 and 2 disclose derivatives having excellent δ receptor agonist activity, which are represented by the following formula:
[0004] [ka]
[0005] The production of these derivatives requires a multi-step synthesis, and therefore it is desirable to have a high yield in each reaction and a high purity of the target compound obtained in each reaction. For example, paragraph
[0025] of Patent Document 1 discloses a method in which a phenyl group is introduced into a phenol (b-1) at the 4-position of a morphinan derivative by Ullmann reaction to obtain (m), and then the oxygen functional group at the 4-position is removed to obtain (n).
[0006] [ka]
[0007] In the Ullmann reaction, copper powder (zero-valent copper) is used to introduce a phenyl group into a morphinan derivative.
[0008] On the other hand, Non-Patent Document 1 discloses a method in which divalent copper (copper(II) acetate) is used to introduce a phenyl group into a morphinan derivative by Ullmann reaction to construct a diaryl ether. [Prior art documents] [Patent documents]
[0009] [Patent Document 1] International Publication No. 2013 / 035833 [Patent Document 2] International Publication No. 2016 / 148232 [Non-patent literature]
[0010] [Non-Patent Document 1] Helvetica Chimica Acta 1990, 73(2), 326-336 Summary of the Invention [Problem to be solved by the invention]
[0011] According to Example 2 of Patent Document 1, when introducing a phenyl group by the Ullmann reaction, even if a theoretical equivalent amount of copper powder is added, the reaction does not go to completion, and copper powder must be added midway through, which presents a problem with reproducibility and means that this method must be said to be unsuitable for industrialization. Therefore, one object of the present invention is to provide a method for producing a morphinan derivative having a diaryl ether skeleton, which method is applicable to industrial production. [Means for solving the problem]
[0012] As a result of extensive investigations, the present inventors have discovered a previously unknown catalytic system using a monovalent copper compound as a catalytic system for producing diaryl ethers by the Ullmann reaction, in particular a novel catalytic system using a monovalent copper compound and zero-valent metallic copper simultaneously, thereby completing the present invention. That is, according to the present invention, the following inventions are provided.
[0013] [1] The following general formula (I): [ka] (In the formula, R 1 is a hydrogen atom, optionally substituted C 1-10 Alkyl group, optionally substituted C 3-6 Cycloalkyl C 1-6 an alkyl group, an aralkyl group which may have a substituent, a heteroarylalkyl group which may have a substituent, a C 3-6 Cycloalkyl group, optionally substituted C 6-10 Aryl group, optionally substituted heteroaryl group, optionally substituted C 2-6 represents an alkenyl group or an amino protecting group, R 2 , R 3 and R 4 are the same or different and represent a hydrogen atom or an arbitrary substituent, Or the general formula (I) [ka] Regarding the part, R 2 and R 4 are combined with each other, [ka] (In the formula, a double line consisting of a solid line and a dashed line represents a single bond or a double bond, Here, when the double line consisting of a solid line and a dashed line between A and B is a single bond, A and B may be the same or different and may be CR 6 R 7 , C=O or NR 8 where R 6 and R 7 are the same or different and each represents a hydrogen atom, -C(=O)-R 9 or -CR 10 (OH)-R 11 R 8 ~R 11 represents a hydrogen atom or an arbitrary substituent, When the double line consisting of a solid line and a dashed line between A and B is a double bond, A and B may be the same or different and may be CR 6 or N, where R 6 , R 9 ~R 11 represents the same as above, The double line consisting of a solid line and a dashed line between D-D represents that if it is a single bond, D represents CH2, and if it is a double bond, D represents CH) Or R 2 ~R 4 are combined with each other, [ka] (Wherein, X is CH2, NR 8 (R 8 represents a hydrogen atom or an arbitrary substituent) or O, Y represents CH2 or C=O, R 12 represents an amino-protecting group or an acyl group, R 5 is a hydrogen atom, a hydroxyl group or -OR 13 (R 13 represents a hydroxy protecting group. and a compound represented by the following general formula (II): [ka] (In the formula, R 14and R 15 are the same or different and represent a hydrogen atom or an arbitrary substituent, and Hal represents a halogen atom. and a compound represented by The method includes reacting the compound in an organic solvent in the presence of a base, a monovalent copper compound, and / or zero-valent metallic copper. The following general formula (III): [ka] (In the formula, R 1 ~R 15 , A, B, D, X and Y are the same as above. The present invention relates to a method for producing a morphinan derivative represented by the formula: [2] The double line consisting of a solid line and a dashed line between A and B represents a single bond, and A and B may be the same or different and may form a CR 6 R 7 R 6 and R 7 are the same or different and are a hydrogen atom or -C(=O)-R 9 R 9 But, C 1-10 Alkyl group, C 1-10 Alkoxy group, C 6-10 The present invention relates to the production method according to the above-mentioned [1], wherein the double line consisting of a solid line and a dashed line between D--D represents an aryl group or NHBn, and D represents CH. [3] The double line consisting of a solid line and a dashed line between A and B represents a single bond, and A and B may be the same or different and may form a CR 6 R 7 R 6 and R 7 are the same or different and are a hydrogen atom or -C(=O)-R 9 R 9 But, C 1-10 Alkyl group, C 1-10 Alkoxy group, C 6-10 represents an aryl group or NHBn, the double line consisting of a solid line and a dashed line between D--D represents a single bond, and D represents CH2, in the production method according to the above-mentioned [1]. [4] The double line consisting of a solid line and a dashed line between A and B represents a single bond, and A and B may be the same or different and may form a CR 6 R 7 R 6 and R 7 are the same or different and are a hydrogen atom or -CR 10 (OH)-R 11 R 10 and R 11 are the same or different and are a hydrogen atom, C 1-10 Alkyl group, C 6-10 represents an aryl group or a heteroaryl group, the double line consisting of a solid line and a dashed line between D and D represents a single bond, and D represents CH2. [5] The general formula (I) is the following general formula (IV): [ka] (In the formula, R 1 ~R 13 X and Y are the same as defined above, The general formula (III) is the following general formula (V): [ka] (In the formula, R 1 ~R 15 2. The method according to claim 1, wherein the morphinan derivative is represented by the formula (I), [6] R 1 wherein R is a methyl group, a cyclopropylmethyl group, a cyclobutylmethyl group, a benzyl group or an allyl group. [7] R 1 The present invention relates to the process according to any one of the above items [1] to [5], wherein [8] R 1 The present invention relates to the process according to any one of the above items [1] to [5], wherein [9] R 5is a hydroxy group or -OR 13 (R 13 represents a hydroxy-protecting group).
[10] R 5 But -OR 13 Where R 13 The present invention relates to the process according to any one of the above items [1] to [8], wherein
[11] R 5 But -OR 13 Where R 13 The present invention relates to the process according to any one of the above items [1] to [8], wherein
[12] The present invention relates to the process according to any one of the above items [1] to
[11] , wherein X is CH2.
[13] The present invention relates to the process according to any one of the above items [1] to
[12] , wherein Y is CH2.
[14] R 12 The present invention relates to the process according to any one of the above items [1] to
[13] , wherein
[15] R 12 C substituted with 1 to 3 fluorines 1-10 Alkyl group or unsubstituted C 1-10 Pyridine optionally substituted with 1 to 4 substituents selected from alkyl groups, 1-oxide carbonyl, or C substituted with 1 to 3 fluorines 1-10 Alkyl group or unsubstituted C 1-10 The present invention relates to the production method according to any one of the above [1] to
[13] , wherein the compound is pyridin-2(1H)-onecarbonyl which may be substituted with 1 to 4 substituents selected from alkyl groups.
[16] R 5 But -OR 13 Where R 13 is a methyl group or other hydroxy protecting group, and wherein X represents CH2 or O.
[17] R 1 is a cyclopropylmethyl group or a methyl group, and wherein X represents CH2 or O.
[18] The general formula (I) [ka] A compound represented by the formula: The general formula (II) [ka] (In the formula, R 14 represents a hydrogen atom or a tert-butyl group), and The general formula (III) [ka] (In the formula, R 14 represents a hydrogen atom or a tert-butyl group),
[19] The present invention relates to the method according to any one of the above items [1] to
[18] , wherein the monovalent copper compound is at least one selected from the group consisting of cuprous chloride, cuprous bromide, cuprous iodide, cuprous oxide, and cuprous complexes.
[20] The present invention relates to the method according to any one of the above items [1] to
[18] , wherein the monovalent copper compound is cuprous iodide or cuprous oxide. [twenty one] The present invention relates to the method according to any one of the above items [1] to
[20] , in which the monovalent copper compound is used in an amount of 0.01 to 2.0 equivalents relative to the compound represented by general formula (I). [twenty two] The present invention relates to the process according to any one of the above items [1] to
[21] , wherein the reaction is carried out in the presence of a monovalent copper compound and zero-valent metallic copper. [twenty three] The present invention relates to the production method according to the above item
[22] , in which 0.01 to 2.0 equivalents of zero-valent metallic copper are used relative to the compound represented by general formula (I). [twenty four] The present invention relates to the method according to the above
[22] or
[23] , wherein the molar ratio of the monovalent copper compound to zero-valent metallic copper (monovalent copper: zero-valent copper) is 1:0.2 to 1:6. [twenty five] The present invention relates to the process according to any one of the above items [1] to
[21] , wherein the reaction is carried out in the absence of zero-valent metallic copper and in the presence of a monovalent copper compound.
[26] The present invention relates to the process according to any one of the above items [1] to
[25] , wherein the organic solvent is an aprotic polar solvent.
[27] The present invention relates to the production method according to the above
[26] , wherein the aprotic polar solvent is at least one selected from the group consisting of pyridine and dimethyl sulfoxide.
[28] The present invention relates to the process according to any one of the above items [1] to
[27] , wherein the base is an alkali metal salt.
[29] The present invention relates to the method for producing a phosphate-based inorganic oxide according to the above-mentioned
[28] , wherein the salt of an alkali metal is at least one selected from the group consisting of carbonates, hydrogen carbonates, phosphates and hydrogen phosphates.
[30] The present invention relates to the process according to any one of the above items [1] to
[29] , wherein the reaction temperature is 50°C to 150°C.
[31] The present invention relates to the method according to any one of the above items [1] to
[30] , wherein the monovalent copper compound is powdered cuprous oxide, and the powder has a particle size of 10 to 100 nm. Effect of the Invention
[0014] The present invention has an advantage that a morphinan derivative can be phenol-etherified with a high conversion rate and high purity. Therefore, the production method of the present invention can industrially advantageously produce a morphinan derivative having a diaryl ether skeleton. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0015] The meanings of the terms used in this specification will be explained below to further explain the present invention. Note that the explanations of the terms below are not intended to limit the present invention in any way.
[0016] The term “C 1-10 The term "alkyl group" refers to a linear or branched acyclic saturated hydrocarbon having 1 to 10 carbon atoms. The alkyl group preferably contains 1 to 6 carbon atoms, more preferably 1 to 4 carbon atoms. Examples of the alkyl group include a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, a tert-butyl group, a pentyl group, a neopentyl group, and a hexyl group.
[0017] The term “C 2-6 The term "alkenyl group" refers to a straight-chain or branched acyclic unsaturated hydrocarbon having one or more carbon-carbon double bonds and having 2 to 6 carbon atoms. Examples of the alkenyl group include an ethenyl group, an allyl group, a 1-propen-2-yl group, a 2-propen-1-yl group, a 1,3-butadiene-1-yl group, and a 1,3-butadiene-2-yl group. C aryl groups having 2 to 4 carbon atoms are preferred. 2-4 It is an alkenyl group.
[0018] The term “C 3-6 "Cycloalkyl group" means saturated monocyclic and polycyclic hydrocarbon groups having 3 to 6 carbon atoms, and polycyclic hydrocarbon groups may contain spiro rings, fused rings and bridged rings. Monocyclic cycloalkyl groups include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like. Examples of the spiro ring in the polycyclic hydrocarbon group include a spiro[2.2]pentyl group, a spiro[2.3]hexyl group, a spiro[3.3]heptyl group, a spiro[3.5]nonyl group, and a spiro[4.5]decanyl group. Examples of the fused ring in the polycyclic hydrocarbon group include a bicyclo[4.2.0]octyl group, a bicyclo[3.2.0]heptyl group, a decahydronaphthyl group, and an octahydroindenyl group. Examples of the bridged ring in the polycyclic hydrocarbon group include a norbornyl group, a bicyclo[2.2.2]octyl group, and an adamantyl group.
[0019] The term “C 3-6 Cycloalkyl C 1-6 The term "alkyl group" means an alkyl group having 1 to 6 carbon atoms substituted with the above cycloalkyl group. Examples of the cycloalkyl alkyl group include a cyclopropylmethyl group, a cyclopropylethyl group, a cyclopropylpropyl group, a cyclobutylmethyl group, a cyclobutylethyl group, a cyclobutylpropyl group, a cyclopentylmethyl group, a cyclopentylethyl group, a cyclopentylpropyl group, a cyclohexylmethyl group, a cyclohexylethyl group, and a cyclohexylpropyl group.
[0020] The term “C 6-10 The term "aryl group" refers to a monocyclic or polycyclic aromatic hydrocarbon having 6 to 10 carbon atoms, at least a portion of which is an aromatic ring structure. Examples of the aryl group include a phenyl group, a naphthyl group, an indanyl group, an indenyl group, and an azulenyl group.
[0021] The term "heteroaryl group" means a monocyclic or polycyclic heterocyclic aromatic ring containing at least one heteroatom selected from nitrogen, oxygen and sulfur atoms, which may be optionally oxidized to various oxidation states. Examples of the monocyclic heteroaryl group include 5-membered ring heteroaryl groups such as a furanyl group, a thienyl group, a pyrrolyl group, an imidazolyl group, a pyrazolyl group, an oxazolyl group, an isoxazolyl group, a thiazolyl group, an isothiazolyl group, a triazolyl group, and a tetrazolyl group; and 6-membered ring heteroaryl groups such as a pyridyl group, a pyridazinyl group, a pyrazinyl group, and a pyrimidyl group. Examples of polycyclic heteroaryl groups include polycyclic heteroaryl groups such as a quinolyl group, an isoquinolyl group, a quinazolyl group, a quinoxalyl group, an indolyl group, an indazolyl group, a benzimidazolyl group, a benzofuranyl group, a benzothienyl group, a benzoxazolyl group, a benzothiazolyl group, an imidazopyridinyl group, and a pyrazolopyridinyl group.
[0022] The term "heteroarylalkyl group" refers to an alkyl group as defined above substituted with a heteroaryl group as defined above. Examples of the heteroarylalkyl group include a furanylmethyl group, a pyridylmethyl group, and a quinolylmethyl group.
[0023] The term "aralkyl group" refers to an alkyl group as defined above substituted with an aryl group such as a phenyl group. Examples of aralkyl groups include benzyl, phenethyl, and phenylpropyl.
[0024] The term "acyl group" refers to a carbonyl having a substituent, such as an alkanoyl group and an aroyl group. The alkanoyl group includes -C(O)-the alkyl group, -C(O)-the cycloalkyl group, and -C(O)-the aralkyl group, and the aroyl group includes -C(O)-the aryl group and -C(O)-the heteroaryl group, and the alkyl group, the aryl group, and the like may have a substituent. Examples of the acyl group include C groups such as a formyl group, an acetyl group, a propionyl group, a butanoyl group, a pentanoyl group, and a hexanoyl group. 2-6 Alkanoyl group; cyclopropanecarbonyl group, cyclobutanecarbonyl group, cyclopentanecarbonyl group, etc. 4―7 Examples of the aroyl group include a cycloalkanecarbonyl group; aroyl groups such as a benzoyl group and a naphthoyl group; and 5- to 6-membered heteroaroyl groups such as a furoyl group, a thiophenecarbonyl group, a nicotinoyl group and an isonicotinoyl group. Furthermore, pyridine 1-oxide carbonyls include pyridine 1-oxide-2-carbonyl, pyridine 1-oxide-3-carbonyl, and pyridine 1-oxide-4-carbonyl, and pyridine-2(1H)-one carbonyls include pyridine-2(1H)-one-3-carbonyl, pyridine-2(1H)-one-4-carbonyl, pyridine-2(1H)-one-5-carbonyl, and pyridine-2(1H)-one-6-carbonyl.
[0025] The term "halogen atom" refers to a fluorine atom, a chlorine atom, a bromine atom, or an iodine atom.
[0026] The term "amino-protecting group" refers to a group suitable for protecting an amino group against chemical reactions and capable of being removed after a desired chemical reaction has been carried out. Examples of amino-protecting groups include, but are not limited to, methoxymethyl, benzyl, formyl, acetyl, trifluoroacetyl, tert-butoxycarbonyl, allyloxycarbonyl, 2,2,2-trichloroethoxycarbonyl, benzyloxycarbonyl, 9-fluorenylmethyloxycarbonyl, p-toluenesulfonyl, and 2-nitrobenzenesulfonyl groups. For example, the protecting groups described in Green's Protective Groups in Organic Synthesis, 5th ed. can be used.
[0027] The term "hydroxy-protecting group" refers to a group suitable for protecting a hydroxy group against chemical reactions and capable of being removed after a desired chemical reaction has been carried out. Examples of the hydroxy-protecting group include, but are not limited to, alkyl groups which may have a substituent such as a methyl group, a methoxymethyl group, or an ethoxyethyl group, aralkyl groups which may have a substituent such as a benzyl group, a 4-methoxybenzyl group, or a trityl group, alkanoyl groups such as an acetyl group, and silyl groups which have a substituent such as a trimethylsilyl group or a tert-butyldimethylsilyl group. For example, the protecting groups described in Green's Protective Groups in Organic Synthesis, 5th ed., etc., can be used.
[0028] The term "optionally substituted" means that it is unsubstituted or substituted with any substituent. The number of substituents and the substitution positions are not particularly limited, and when two or more substituents are present, they may be the same or different.
[0029] The term "optional substituent" refers to any group other than a hydrogen atom, and typical substituents include, but are not limited to, alkyl groups, alkenyl groups, alkynyl groups, alkoxy groups, hydroxyl groups, cyano groups, nitro groups, halogen groups, carboxyl groups, alkoxycarbonyl groups, acyl groups, mercapto groups, alkylthio groups, sulfonyl groups, alkylsulfonyl groups, sulfinyl groups, alkylsulfinyl groups, sulfonamido groups, alkanesulfonamido groups, carbamoyl groups, thiocarbamoyl groups, aminocarbonyl groups, aminosulfonyl groups, amino groups, mono- or dialkylamino groups, carbonylamino groups, acyloxy groups, oxo groups, thiooxo groups, cycloalkyl groups, heterocycloalkyl groups, aryl groups, heteroaryl groups, aralkyl groups, aryloxy groups, heteroaryloxy groups, aralkyloxy groups, arylthio groups, heteroarylthio groups, and aralkylthio groups.
[0030] The production method of the present invention can produce a morphinan diaryl ether derivative represented by general formula (III) using a morphinan derivative represented by general formula (I) and a halobenzene derivative represented by general formula (II).
[0031] [ka]
[0032] The morphinan derivative represented by the general formula (I) can be produced by the method described in Patent Document 1 or a method similar thereto. In addition, commercially available products (e.g., thebainone and ketorphanol) can also be prepared by known methods and used.
[0033] The halobenzene derivative represented by the general formula (II) can be commercially available or can be produced by a method known to those skilled in the art.
[0034] The "base" to be added to the reaction may be an alkali metal carbonate such as sodium carbonate, potassium carbonate, or cesium carbonate, or a hydrogen carbonate; an alkali metal phosphate such as potassium phosphate, or a hydrogen phosphate; an amine such as trimethylamine or triethylamine; or a metal halide such as potassium fluoride or cesium fluoride. Potassium carbonate, sodium carbonate, or potassium phosphate is preferred, and potassium phosphate is more preferred.
[0035] The copper catalyst used in the present invention is not particularly limited, and any known copper catalyst used in the Ullmann reaction can be used. Examples of "monovalent copper compounds" include cuprous chloride, cuprous bromide, copper iodide, cuprous oxide, and cuprous complexes. CuI (copper iodide) or Cu2O (copper(I) oxide) is preferred because the ligand does not become an impurity after the reaction and purification is easy. So-called nanoparticle Cu2O with a particle diameter of 10 to 100 nm, 30 to 70 nm, and particularly 50 nm is preferred. Examples of the cuprous complex include pyridine-2-carboxylic acid, dipivaloylmethane, N,N-dimethylglycine, 1,10-phenanthroline, proline, 2-thiophenecarboxylic acid, 2,2'-bipyridyl, ethyl 2-oxocyclohexanecarboxylate, 3,4,7,8-tetramethyl-1,10-phenanthroline, and N,N-dimethylethylenediamine.
[0036] Examples of "zero-valent copper" include metallic copper and copper complexes. Metallic copper may be in the form of powder, mesh, rod, plate, kettle, etc., with the powder form being preferred since it has a relatively large specific surface area. For the powder form, commercially available products can be used as is.
[0037] The monovalent copper compound can be used in an amount of, for example, 0.01 to 2.0 equivalents, 0.02 to 2.0 equivalents, 0.05 to 1.5 equivalents, 0.1 to 1.0 equivalents, 0.15 to 1.0 equivalents, 0.2 to 1.0 equivalents, 0.25 to 1.0 equivalents, 0.3 to 1.0 equivalents, or 0.5 to 1.0 equivalent relative to the compound represented by general formula (I).
[0038] Zero-valent metallic copper can be used in an amount of, for example, 0.01 to 2.0 equivalents, 0.1 to 1.5 equivalents, 0.2 to 1.0 equivalents, 0.45 to 1.0 equivalents, 0.5 to 1.0 equivalents, 0.6 to 1.0 equivalents, or 0.85 to 1.0 equivalents relative to the compound represented by general formula (I).
[0039] When a monovalent copper compound and zero-valent metallic copper are used simultaneously, the converted molar ratio of the two (monovalent copper: zero-valent copper) can be, for example, 1:0.2, 1:0.45, 1:0.5, 1:1, 1:1.33, 1:2, 1:4, 1:5.67, 1:6, and more preferably 1:4.
[0040] The solvent used in the reaction is not particularly limited as long as it is an organic solvent, but an aprotic polar solvent is preferred. Examples of the aprotic polar solvent include tetrahydrofuran (THF), 2-methyltetrahydrofuran (2-MeTHF), formamide, N-methylformamide, dimethylformamide (DMF), N-methylacetamide, dimethylacetamide (DMAC), N-methylpyrrolidinone (NMP), dimethyl sulfoxide (DMSO), acetonitrile, propionitrile, acetone, ethyl methyl ketone, methyl acetate, ethyl acetate, sulfolane, tetramethylurea, hexamethylphosphoramide , 2 Trobene Nma or pyridine and the like. These can be used alone or in combination of two or more. In the present invention, DMSO and pyridine are preferred, and pyridine is more preferred.
[0041] The reaction temperature varies depending on the types of the raw material compound, the reaction reagent or the solvent used. For example, it can be carried out in the range from room temperature to the boiling point of the solvent. For example, it can be carried out at 20°C to 200°C, 25°C to 200°C, 50°C to 180°C, 50°C to 150°C, 80°C to 150°C, 100°C to 130°C, and more preferably at 110°C to 120°C.
Examples
[0042] The present invention will be further clarified by the following reference examples and examples, but the present invention is not limited to these examples. The names of the compounds in the examples and reference examples were translated into Japanese after converting the structural formulas drawn using ChemDraw ver.14 or ver.18 manufactured by CambridgeSoft into English names by the naming algorithm installed in the same software.
[0043] The product was identified by the coincidence of the elution time with that of the standard product by HPLC analysis. Also, the conversion rate and purity of the reaction were calculated from the peak areas of the remaining raw materials and the product. <HPLC conditions> Column: ZORBAX Bonus-RP (Agilent), 4.6 x 150 mm, particle size 3.5 μm Column temperature: 35℃ Detection: 204nm (DAD) ·Flow rate: 1.0mL / min Mobile phase: Solution A = 0.05% TFA aqueous solution, Solution B = 0.05% TFA acetonitrile Gradient conditions: 0 minutes to 12 minutes A:B = 95:5 to A:B = 10:90 (gradation) 12 minutes to 16 minutes A solution: B solution = 10:90 (continuous) ·Holding time: (1S,3aR,5aS,6R,11bS,11cS)-3-benzyl-14-(cyclopropylmethyl)-10-methoxy-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indol-11-ol approx. 5.4 min (1S,3aR,5aS,6R,11bS,11cS)-3-Benzyl-11-(4-(tert-butyl)phenoxy)-14-(cyclopropylmethyl)-10-methoxy-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indole 7.2-7.3 min ( 1S,3aR,5aS,6R,11bS,11cS)-3-Benzyl -1 4-(Cyclopropylmethyl) -1 0-Methoxy-11-phenoxy-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indole Approx. 6.3 min
[0044] Synthesis of (1S,3aR,5aS,6R,11bS,11cS)-3-benzyl-11-(4-(tert-butyl)phenoxy)-14-(cyclopropylmethyl)-10-methoxy-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indole [ka]
[0045] Example 1 (1S,3aR,5aS,6R,11bS,11cS)-3-benzyl-14-(cyclopropylmethyl)-10-methoxy-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indol-11-ol (286g, 1eq) was dissolved in pyridine (4.3L) and bubbled with nitrogen for 10 minutes. Potassium phosphate tripotassium (259g, 2eq) was added, and the mixture was replaced with nitrogen three times and then bubbled for 15 minutes. After stirring at 95-105°C for 1 hour, copper powder (39.0g, 1 equivalent), cuprous oxide (average particle size 50 nm, 22.0g, 0.25 equivalent) and 4-tert-butylbromobenzene (650g, 5 equivalents) were added with stirring at 95-105°C, and then stirred at 110-120°C for 16 hours. HPLC analysis of the reaction solution showed a conversion rate of 99.35% and a purity of 96.14%. The reaction mixture was cooled to room temperature, and then filtered through a silica gel pad to remove insoluble matter. The filtrate was concentrated, and the silica gel pad was washed twice with methyl tert-butyl ether (4.3 L, 430 mL), and added to the organic layer. The combined organic layers were then washed three times (2.86 L x 3) with 8.3%-9.3% aqueous ammonia. The combined aqueous layers were extracted once (1.43 L) with methyl tert-butyl ether. The combined organic layers were washed three times (2.86 L x 3) with water. Water (4.3 L) was added to the organic layer, and 4N hydrochloric acid was added to adjust the pH of the aqueous layer to 2-3, and the organic layer was separated. The aqueous layer was washed twice with methyl tert-butyl ether (1.43 L x 2) and concentrated to remove residual methyl tert-butyl ether. The aqueous layer was mixed with 25-28% aqueous ammonia to adjust the pH to 9, and then stirred at room temperature for 30 minutes. The precipitate was collected by filtration and washed with water (858 mL). The solid was dried to obtain the title compound (315 g, 81.63% yield, 92.90% purity).
[0046] 1H-NMR (400MHz, CDCl3): δ7.10-7.35(m,7H),6.97(d,1H,J=8Hz),6.77(d,1H,J=8Hz),6.67(d,2H,J=8Hz),3.70 (d,1H,J=13Hz),3.68(s,3H),3.55(d,1H,J=13Hz),2.90-3.20(m,6H),2.60-2.70(m,1H),2.46(dd,1H,J=4,12H z),2.29(d,2H,J=6Hz),1.99(dt,1H,J=3,13Hz),1.75(dt,1H,J=5,13Hz),1.50-1.65(m,3H),1.30(s,9H),1.2 0-1.35(m,1H),1.10-1.20(m,1H),1.00-1.10(m,2H),0.70-0.85(m,2H),0.40-0.50(m,2H),0.00-0.15(m,2H).
[0047] Example 2 Pyridine (4 mL) was added to the reactor and nitrogen was bubbled in for 10 minutes. (1S,3aR,5aS,6R,11bS,11cS)-3-benzyl-14-(cyclopropylmethyl)-10-methoxy-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indol-11-ol (0.4 g, 1 eq.) was added to the reactor and dissolved. Potassium phosphate tripotassium (0.36 g, 2 eq.) was added and replaced with nitrogen three times, followed by bubbling for 15 minutes. After stirring at 95-105° C. for 1 hour, cuprous oxide (0.12 g, 1 equivalent) and 4-tert-butylbromobenzene (0.91 g, 5 equivalents) were added at 95-105° C., and the mixture was then stirred at 110-120° C. for 16 hours. HPLC analysis of the reaction solution showed a conversion rate of 100% and a purity of 76.99%.
[0048] Example 3 Pyridine (10 mL) was added to the reactor and nitrogen was bubbled in for 10 minutes. (1S,3aR,5aS,6R,11bS,11cS)-3-benzyl-14-(cyclopropylmethyl)-10-methoxy-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indol-11-ol (1.0 g, 1 eq.) was added to the reactor and dissolved. Potassium phosphate tripotassium (0.90 g, 2 eq.) was added and replaced with nitrogen three times, followed by bubbling for 15 minutes. After stirring at 95-105° C. for 1 hour, cuprous oxide (61.3 mg, 0.2 equivalents) and 4-tert-butylbromobenzene (2.27 g, 5 equivalents) were added at 95-105° C., and the mixture was then stirred at 110-120° C. for 16 hours. HPLC analysis of the reaction solution showed a conversion rate of 92.8% and a purity of 76.71%.
[0049] Example 4 Pyridine (20 mL) was added to the reactor and nitrogen was bubbled in for 10 minutes. (1S,3aR,5aS,6R,11bS,11cS)-3-benzyl-14-(cyclopropylmethyl)-10-methoxy-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indol-11-ol (2.0 g, 1 eq.) was added to the reactor and dissolved. Potassium phosphate tripotassium (1.80 g, 2 eq.) was added and replaced with nitrogen three times, followed by bubbling for 15 minutes. After stirring at 95-105° C. for 1 hour, copper powder (54.6 mg, 0.2 equivalents), cuprous oxide (92 mg, 0.15 equivalents) and 4-tert-butylbromobenzene (4.54 g, 5 equivalents) were added at 95-105° C., and the mixture was stirred at 110-120° C. for 16 hours. HPLC analysis of the reaction solution showed a conversion rate of 99.18% and a purity of 83.33%.
[0050] Example 5 Pyridine (20 mL) was added to the reactor and nitrogen was bubbled in for 10 minutes. (1S,3aR,5aS,6R,11bS,11cS)-3-benzyl-14-(cyclopropylmethyl)-10-methoxy-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indol-11-ol (2.0 g, 1 eq.) was added to the reactor and dissolved. Potassium phosphate tripotassium (1.80 g, 2 eq.) was added and replaced with nitrogen three times, followed by bubbling for 15 minutes. After stirring at 95-105°C for 1 hour, copper powder (54.6mg, 0.2eq), copper iodide (0.81g, 1eq) and 4-tert-butylbromobenzene (4.54g, 5eq) were added at 95-105°C, and then stirred at 110-120°C for 16 hours. HPLC of the reaction solution showed a conversion rate of 92.4% and a purity of 84.66%. Copper powder (68mg, 0.25eq) was added to the reactor, and then stirred at 110-120°C for 4 hours. HPLC of the reaction solution showed a conversion rate of 99.1% and a purity of 88.78%.
[0051] Example 6 Pyridine (50 mL) was added to the reactor and nitrogen was bubbled in for 10 minutes. (1S,3aR,5aS,6R,11bS,11cS)-3-benzyl-14-(cyclopropylmethyl)-10-methoxy-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indol-11-ol (5.0 g, 1 eq.) was added to the reactor and dissolved. Potassium phosphate tripotassium (4.51 g, 2 eq.) was added and replaced with nitrogen three times, followed by bubbling for 15 minutes. After stirring at 95-105°C for 1 hour, copper powder (0.41g, 0.6 eq), cuprous oxide (0.23g, 0.15 eq) and 4-tert-butylbromobenzene (11.33g, 5 eq) were added at 95-105°C and then stirred at 110-120°C for 16 hours. HPLC of the reaction solution showed a conversion of 90.20% and a purity of 85.54%. Copper powder (0.17g, 0.25 eq) was added to the reactor and then stirred at 110-120°C for 3 hours. HPLC of the reaction solution showed a conversion of 93.58% and a purity of 86.93%. Copper powder (0.17g, 0.25 eq) was added to the reactor and then stirred at 110-120°C for 2 hours. HPLC analysis of the reaction solution revealed a conversion rate of 97.88% and a purity of 91.27%. The reaction mixture was cooled to room temperature and then filtered through a silica gel pad to remove insoluble matter. The silica gel pad was washed with methyl tert-butyl ether (10 mL) and added to the organic layer. The combined organic layers were then concentrated to 5-10 mL, and methyl tert-butyl ether (75 mL) was added to make a dark brown suspension. The organic layers were then washed three times (50 mL x 3) with 13%-14% aqueous ammonia. The aqueous layers were combined and extracted with methyl tert-butyl ether (25 mL). The organic layers were combined and washed with water (50 mL). Water (75 mL) was added to the organic layer, and then 4N hydrochloric acid was added to adjust the pH of the aqueous layer to 3-4, and the organic layer was separated. The aqueous layer was washed with methyl tert-butyl ether (25 mL) and concentrated to remove residual methyl tert-butyl ether. The aqueous layer was heated to 50-55°C, 25-28% aqueous ammonia was added, the pH was adjusted to 8-9, and the mixture was cooled to room temperature. The precipitate was collected by filtration, washed with water (10 mL), and dried to obtain the title compound (5.2 g, 81.98% yield, purity 93.95%).
[0052] Example 7 Pyridine (4 mL) was added to the reactor and nitrogen was bubbled in for 10 minutes. (1S,3aR,5aS,6R,11bS,11cS)-3-benzyl-14-(cyclopropylmethyl)-10-methoxy-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indol-11-ol (0.4 g, 1 eq.) was added to the reactor and dissolved. Potassium phosphate tripotassium (0.36 g, 2 eq.) was added and replaced with nitrogen three times, followed by bubbling for 15 minutes. After stirring at 95-105° C. for 1 hour, 2-thiophenecarboxylic acid (11 mg, 0.1 equivalent), copper iodide (16 mg, 0.1 equivalent) and 4-tert-butylbromobenzene (0.91 mg, 5 equivalents) were added at 95-105° C., and the mixture was stirred at 110-120° C. for 16 hours. HPLC analysis of the reaction solution showed a conversion rate of 89.8% and a purity of 75.8%.
[0053] Example 8 DMSO (2 mL) was added to the reactor and nitrogen was bubbled in for 10 minutes. (1S,3aR,5aS,6R,11bS,11cS)-3-benzyl-14-(cyclopropylmethyl)-10-methoxy-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indol-11-ol (0.2 g, 1 eq.) was added to the reactor and dissolved. Potassium phosphate tripotassium (0.18 g, 2 eq.) was added and replaced with nitrogen three times, followed by bubbling for 15 minutes. After stirring at 95-105° C. for 1 hour, 2-thiophenecarboxylate copper(I) (8.1 mg, 0.1 equivalent) and 4-tert-butylbromobenzene (0.45 g, 5 equivalent) were added at 95-105° C., and the mixture was stirred at 110-120° C. for 16 hours. HPLC analysis of the reaction solution showed a conversion rate of 95.92% and a purity of 45.60%.
[0054] Synthesis of (1S,3aR,5aS,6R,11bS,11cS)-3-benzyl-14-(cyclopropylmethyl)-10-methoxy-11-phenoxy-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indole [ka]
[0055] Example 9 Pyridine (20 mL) was added to the reactor and nitrogen was bubbled in for 10 minutes. (1S,3aR,5aS,6R,11bS,11cS)-3-benzyl-14-(cyclopropylmethyl)-10-methoxy-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indol-11-ol (2.0 g, 1 equiv.) was added to the reactor and dissolved. Potassium tert-butoxide (0.48 g, 1 equiv.) and tripotassium phosphate (0.9 g, 1 equiv.) were added and replaced with nitrogen three times, followed by bubbling for 15 minutes. After stirring at 95-105° C. for 1 hour, copper powder (54.6 mg, 0.2 equivalents), cuprous oxide (92 mg, 0.15 equivalents) and bromobenzene (3.33 g, 5 equivalents) were added at 95-105° C., and the mixture was stirred at 110-120° C. for 16 hours. HPLC analysis of the reaction solution showed a conversion rate of 99.6% and a purity of 95.61%.
[0056] Example 10 Pyridine (50 mL) was added to the reactor and nitrogen was bubbled in for 10 minutes. (1S,3aR,5aS,6R,11bS,11cS)-3-benzyl-14-(cyclopropylmethyl)-10-methoxy-2,3,3a,4,5,6,7,11c-octahydro-1H-6,11b-(epiminoethano)-1,5a-methanonaphtho[1,2-e]indol-11-ol (5.0 g, 1 eq.) was added to the reactor and dissolved. Potassium phosphate tripotassium (4.51 g, 2 eq.) was added and replaced with nitrogen three times, followed by bubbling for 15 minutes. After stirring at 95-105° C. for 1 hour, copper powder (0.68 g, 1 eq.), cuprous oxide (0.38 g, 0.25 eq.) and bromobenzene (8.35 g, 5 eq.) were added at 95-105° C., and the mixture was stirred at 110-120° C. for 16 hours. HPLC analysis of the reaction solution showed a conversion rate of 99.4% and a purity of 92.88%. [Industrial Applicability]
[0057] The present invention provides an industrial process for producing a morphinan derivative having a diaryl ether skeleton.
Claims
1. The following general formula (IV): 【Chemistry 1】 (In the formula, R 1 is C 3-6 Cycloalkyl C 1-6 represents an alkyl group, R 5 is -OR 13 (R 13 represents a hydroxy protecting group), X represents CH2; Y represents CH2; R 12 represents an amino protecting group) and a compound represented by the following general formula (II): 【Chemistry 2】 (In the formula, R 14 represents a hydrogen atom or an alkyl group, R 15 represents a hydrogen atom, and Hal represents a halogen atom. and a compound represented by The method includes reacting in an organic solvent in the presence of a base and in the presence of a monovalent copper compound and zero-valent metallic copper, or in the presence of a monovalent copper compound and in the absence of zero-valent metallic copper, The following general formula (V): 【Chemistry 3】 (In the formula, R 1 , R 5 , R 12 , X, Y, R 14 and R 15 represents the same as above) A method for producing a morphinan derivative represented by the formula: the base is an alkali metal salt, The monovalent copper compound is cuprous iodide or cuprous oxide, and The organic solvent is an aprotic polar solvent. Manufacturing method.
2. R 1 The method according to claim 1, wherein R is a cyclopropylmethyl group.
3. R 13 The method according to claim 1 or 2, wherein is a methyl group, a benzyl group or a tert-butyldimethylsilyl group.
4. R 13 The method according to claim 1 or 2, wherein is a methyl group.
5. R 12 The method according to any one of claims 1 to 4, wherein is a benzyl group.
6. The general formula (IV) 【Chemistry 4】 A compound represented by the formula: The general formula (II) 【Chemistry 5】 (In the formula, R 14 represents a hydrogen atom or a tert-butyl group), and The general formula (V) 【Chemistry 6】 (In the formula, R 14 represents a hydrogen atom or a tert-butyl group).
7. The monovalent copper compound is used in an amount of 0.01 to 2.0 equivalents relative to the compound represented by the general formula (IV). The method according to any one of claims 1 to 6.
8. The method according to any one of claims 1 to 7, wherein the reaction is carried out in the presence of a monovalent copper compound and zero-valent metallic copper.
9. The method according to claim 8, wherein 0.01 to 2.0 equivalents of zero-valent metallic copper are used relative to the compound represented by general formula (IV).
10. The method according to claim 8 or 9, wherein the molar ratio of the monovalent copper compound to zero-valent metallic copper (monovalent copper: zero-valent copper) is 1:0.2 to 1:
6.
11. The method according to any one of claims 1 to 7, wherein the reaction is carried out in the absence of zero-valent metallic copper and in the presence of a monovalent copper compound.
12. The method according to any one of claims 1 to 11, wherein the aprotic polar solvent is at least one selected from the group consisting of pyridine and dimethylsulfoxide.
13. 13. The method according to any one of claims 1 to 12, wherein the salt of an alkali metal is at least one selected from the group consisting of carbonates, hydrogen carbonates, phosphates and hydrogen phosphates.
14. The method according to any one of claims 1 to 13, wherein the reaction temperature is from 50°C to 150°C.
15. The method according to any one of claims 1 to 14, wherein the monovalent copper compound is powdered cuprous oxide, and the powder has a particle size of 10 to 100 nm.
Citation Information
Patent Citations
Morphinan derivative
WO2013035833A1
Morphinan derivative
WO2014136305A1
Morphinan derivative
WO2016148232A1
